Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Anaptysbio Inc's Business Segments
Anaptysbio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Royalty Management Company
Total Revenue
$ 26
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Royalty Management Company100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty Management Company | $ 26 | 100% |
Description of Anaptysbio Inc
AnaptysBio Inc. is a biotechnology company that focuses on the discovery and development of antibody therapeutics for the treatment of various diseases. The company is headquartered in San Diego, California, and was founded in 2005.
AnaptysBio utilizes its proprietary protein therapeutics technology platform called SHM-XEL to create novel therapeutic antibodies. This platform leverages the natural process of somatic hypermutation (SHM) in the human body to generate high-affinity antibodies with enhanced therapeutic properties. By mimicking this process in the laboratory, AnaptysBio is able to develop antibodies that have improved binding affinity, stability, and efficacy.
The company's research and development efforts are primarily focused on the field of immuno-oncology, where they are developing antibodies to target specific tumor antigens and immune checkpoints. By modulating the immune system's response to cancer, these antibodies have the potential to enhance the efficacy of existing cancer treatments and provide new treatment options for patients.
In addition to immuno-oncology, AnaptysBio is also exploring the therapeutic potential of its antibody candidates in other disease areas such as inflammatory diseases, autoimmune disorders, and rare diseases. The company has a robust pipeline of product candidates at various stages of preclinical and clinical development.
AnaptysBio has established collaborations and partnerships with several pharmaceutical companies, academic institutions, and government organizations to accelerate the development and commercialization of its antibody therapeutics. These collaborations provide the company with access to additional resources, expertise, and funding to advance its research programs.
The company's commitment to innovation and scientific excellence is evident in its extensive intellectual property portfolio, which includes numerous granted and pending patents related to its SHM-XEL platform and antibody candidates.
AnaptysBio has a dedicated team of scientists, researchers, and industry professionals who work collaboratively to drive the company's mission of bringing novel antibody therapeutics to patients in need. The company's success is built on a strong foundation of scientific expertise, cutting-edge technology, and a passion for improving patient outcomes.
In summary, AnaptysBio Inc. is a biotechnology company at the forefront of antibody therapeutics development. With its innovative SHM-XEL platform, the company aims to discover and develop novel antibodies for the treatment of various diseases, particularly in the field of immuno-oncology. Through collaborations and partnerships, AnaptysBio is advancing its pipeline of therapeutic candidates and working towards providing new treatment options for patients worldwide.
AnaptysBio utilizes its proprietary protein therapeutics technology platform called SHM-XEL to create novel therapeutic antibodies. This platform leverages the natural process of somatic hypermutation (SHM) in the human body to generate high-affinity antibodies with enhanced therapeutic properties. By mimicking this process in the laboratory, AnaptysBio is able to develop antibodies that have improved binding affinity, stability, and efficacy.
The company's research and development efforts are primarily focused on the field of immuno-oncology, where they are developing antibodies to target specific tumor antigens and immune checkpoints. By modulating the immune system's response to cancer, these antibodies have the potential to enhance the efficacy of existing cancer treatments and provide new treatment options for patients.
In addition to immuno-oncology, AnaptysBio is also exploring the therapeutic potential of its antibody candidates in other disease areas such as inflammatory diseases, autoimmune disorders, and rare diseases. The company has a robust pipeline of product candidates at various stages of preclinical and clinical development.
AnaptysBio has established collaborations and partnerships with several pharmaceutical companies, academic institutions, and government organizations to accelerate the development and commercialization of its antibody therapeutics. These collaborations provide the company with access to additional resources, expertise, and funding to advance its research programs.
The company's commitment to innovation and scientific excellence is evident in its extensive intellectual property portfolio, which includes numerous granted and pending patents related to its SHM-XEL platform and antibody candidates.
AnaptysBio has a dedicated team of scientists, researchers, and industry professionals who work collaboratively to drive the company's mission of bringing novel antibody therapeutics to patients in need. The company's success is built on a strong foundation of scientific expertise, cutting-edge technology, and a passion for improving patient outcomes.
In summary, AnaptysBio Inc. is a biotechnology company at the forefront of antibody therapeutics development. With its innovative SHM-XEL platform, the company aims to discover and develop novel antibodies for the treatment of various diseases, particularly in the field of immuno-oncology. Through collaborations and partnerships, AnaptysBio is advancing its pipeline of therapeutic candidates and working towards providing new treatment options for patients worldwide.
Anaptysbio Inc. is a clinical-stage biopharmaceutical company primarily focused on the development of differentiated therapeutics for the treatment of serious diseases. The company uses its proprietary technology platform, known as the Aptamer Platform,to develop treatments based on optimized antibodies and other biologics. Below is an extensive overview of the segments, products, and services that Anaptysbio is involved with:
Segments
1. Drug Development: Anaptysbio operates primarily in the biopharmaceutical segment, concentrating on the discovery and development of innovative therapeutic solutions. This process typically includes stages ranging from preclinical research through clinical trials.
2. Therapeutic Areas: The company focuses on several key therapeutic areas, including:
- Immunology: Developing drugs for autoimmune diseases and inflammatory conditions.
- Oncology: Creating therapies aimed at cancer treatment.
- Inflammation: Addressing chronic inflammatory diseases with targeted immunotherapies.
Products
Anaptysbios pipeline includes various product candidates at different stages of clinical development:
1. Anti-PD-1 Antibody: This candidate represents part of the immuno-oncology segment and is aimed at enhancing the immune response against tumors.
2. AnapTcelerator™ Platform: A unique approach toward creating fully-human antibodies. This platform enables rapid optimization of antibody candidates for various diseases, significantly expediting the drug discovery phase.
3. Aptamer Technology: Utilizing pegylation and other engineering techniques, Anaptysbio has developed novel delivery systems and mechanisms for drugs that enhance their therapeutic efficacy and safety profile.
4. Biologics and Biosimilars: Some of their projects may also involve the development of biosimilar products, which are biologic medical products highly similar to already approved reference products. This area is particularly competitive and increasingly important within the pharmaceutical marketplace.
Services
In addition to its product offerings, Anaptysbio also provides various services that enhance its research and development efforts:
1. Collaborative Research: The company may engage with academic institutions and industry partners in collaborative research initiatives, leveraging shared expertise and resources to advance drug development.
2. Clinical Trial Design and Management: Anaptysbio manages its clinical trials, which may involve specific services in designing trials, recruiting participants, and analyzing data to ensure regulatory compliance and successful product development.
3. Regulatory Affairs: The company likely has a dedicated team to handle the complexities of drug approval processes, including interactions with regulatory bodies like the FDA. This is crucial for ensuring that new treatments meet stringent safety and efficacy standards.
4. Partnerships and Licensing: Anaptysbio may engage in strategic partnerships or licensing agreements to expand its research capabilities, enhance product development, or tap into additional funding sources, thereby increasing potential market opportunities.
5. Consulting Services: In some cases, Anaptysbio may offer consulting services based on their expertise in biopharmaceutical development, helping other companies navigate challenges in drug discovery and regulatory hurdles.
Conclusion
Anaptysbio Inc. is positioned in a dynamic segment of the biopharmaceutical industry, focused on innovative therapeutic solutions targeting critical medical needs. With a robust pipeline of product candidates, advanced technology platforms, and dedicated services to support drug development, Anaptysbio is working toward delivering novel treatments for complex diseases, enhancing patient outcomes, and advancing the field of medicine.
Segments
1. Drug Development: Anaptysbio operates primarily in the biopharmaceutical segment, concentrating on the discovery and development of innovative therapeutic solutions. This process typically includes stages ranging from preclinical research through clinical trials.
2. Therapeutic Areas: The company focuses on several key therapeutic areas, including:
- Immunology: Developing drugs for autoimmune diseases and inflammatory conditions.
- Oncology: Creating therapies aimed at cancer treatment.
- Inflammation: Addressing chronic inflammatory diseases with targeted immunotherapies.
Products
Anaptysbios pipeline includes various product candidates at different stages of clinical development:
1. Anti-PD-1 Antibody: This candidate represents part of the immuno-oncology segment and is aimed at enhancing the immune response against tumors.
2. AnapTcelerator™ Platform: A unique approach toward creating fully-human antibodies. This platform enables rapid optimization of antibody candidates for various diseases, significantly expediting the drug discovery phase.
3. Aptamer Technology: Utilizing pegylation and other engineering techniques, Anaptysbio has developed novel delivery systems and mechanisms for drugs that enhance their therapeutic efficacy and safety profile.
4. Biologics and Biosimilars: Some of their projects may also involve the development of biosimilar products, which are biologic medical products highly similar to already approved reference products. This area is particularly competitive and increasingly important within the pharmaceutical marketplace.
Services
In addition to its product offerings, Anaptysbio also provides various services that enhance its research and development efforts:
1. Collaborative Research: The company may engage with academic institutions and industry partners in collaborative research initiatives, leveraging shared expertise and resources to advance drug development.
2. Clinical Trial Design and Management: Anaptysbio manages its clinical trials, which may involve specific services in designing trials, recruiting participants, and analyzing data to ensure regulatory compliance and successful product development.
3. Regulatory Affairs: The company likely has a dedicated team to handle the complexities of drug approval processes, including interactions with regulatory bodies like the FDA. This is crucial for ensuring that new treatments meet stringent safety and efficacy standards.
4. Partnerships and Licensing: Anaptysbio may engage in strategic partnerships or licensing agreements to expand its research capabilities, enhance product development, or tap into additional funding sources, thereby increasing potential market opportunities.
5. Consulting Services: In some cases, Anaptysbio may offer consulting services based on their expertise in biopharmaceutical development, helping other companies navigate challenges in drug discovery and regulatory hurdles.
Conclusion
Anaptysbio Inc. is positioned in a dynamic segment of the biopharmaceutical industry, focused on innovative therapeutic solutions targeting critical medical needs. With a robust pipeline of product candidates, advanced technology platforms, and dedicated services to support drug development, Anaptysbio is working toward delivering novel treatments for complex diseases, enhancing patient outcomes, and advancing the field of medicine.